
Draig Therapeutics, a Welsh clinical-stage company developing glutamate and GABA-based treatments for neuropsychiatry, has appointed Ivana Magovčević-Liebisch as President and …
Amphista doses first patient in AML trial of protein degrader
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand

